A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

Clinical trial NCT04387448 · TERMINATED

Trial details

NCT number: NCT04387448
Sponsor: Goldfinch Bio, Inc.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Kidney Diseases Diabetic Nephropathies Glomerulosclerosis, Focal Segmental Nephrosis, Lipoid Urologic Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Glomerulonephritis Nephritis Nephrosis

Start date: 2020-07-28
Primary completion: 2022-11-01
Enrollment: 96

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.